







INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C07D 473/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/19327</p> <p>(43) International Publication Date: 22 April 1999 (22.04.99)</p>
<p>(21) International Application Number: PCT/GB98/03080</p> <p>(22) International Filing Date: 14 October 1998 (14.10.98)</p> <p>(30) Priority Data: 9721780.6 14 October 1997 (14.10.97) GB</p> <p>(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): JONES, Martin, Francis [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). WALLIS, Christopher, John [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).</p> <p>(74) Agent: PETT, Christopher, Phineas; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: PROCESS FOR THE SYNTHESIS OF CHLOROPURINE INTERMEDIATES</p> <div style="display: flex; justify-content: space-around; align-items: flex-start;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(IV)</p> </div> </div> <div style="display: flex; justify-content: space-around; align-items: flex-start; margin-top: 20px;"> <div style="text-align: center;">  <p>(V)</p> </div> <div style="text-align: center;">  <p>(VI)</p> </div> </div> <p>(57) Abstract</p> <p>The present invention relates to a process for the preparation of a carbocyclic purine nucleoside analogue of formula (I), its salts and pharmaceutically acceptable derivatives thereof which comprises hydrolysing a compound of formula (IV) wherein P is a protecting group, in the presence of an acid, condensing the product of formula (V) formed <i>in situ</i> in the presence of a base with a compound of formula (VI) followed by <i>in situ</i> ring closure of the resulting intermediate.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MR	Mauritania	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

- 1 -

PROCESS FOR THE SYNTHESIS OF CHLOROPURINE INTERMEDIATES


5 The present invention relates to a process for the preparation of a carbocyclic purine nucleoside analogue of formula (I), its salts and pharmaceutically acceptable derivatives thereof.

10 An enantiomerically pure compound of formula (I)



has been described in GB-A-2217320 and can be used as an intermediate in the manufacture of abacavir, a 2-aminopurine nucleoside analogue with the following structure (II)

25




- 2 -

This is described in EP 0434450 as having potent activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

5 There exists a need to synthesise large quantities of abacavir for clinical trials and once abacavir has been approved by the national medicine regulatory agencies, large quantities of abacavir will also be required for sale as a prescription medicine for the treatment of HIV
10 infections.

Processes for the manufacture of abacavir using enantiomerically pure compounds of formula (III)

15




(III)

20 via the 2-aminopurine intermediate of formula (I) are described generally in PCT Publication Nos. WO91/15490, in WO95/21161, in EP 0434450 and in Tetrahedron: Asymmetry Vol. 4, p.1117, (1993). However, the procedures described provide an unsatisfactory route to
25 the 2-aminopurine derivative of formula (I), inasmuch as they require the isolation and purification of a number of intermediates resulting in a relatively high cost and a low yield for the synthesis.

30 We have developed a process for the production of the intermediate of formula (I) from N-protected-4-amino-cyclopentenes of formula (IV)

- 3 -




wherein P is a protecting group,

which provides a high yield and is more cost effective.

The protecting group P will desirably be an acyl or substituted oxycarbonyl group.

One aspect of the present invention comprises an in situ conversion of cyclopentenenes of formula (IV) to 2-aminopurine derivatives of formula (I) easily and conveniently without the need to isolate any intermediates. In our procedure, the deprotection of the starting material of formula (IV) in situ provides the desired amino alcohol without any wasteful workup, and because of the direct coupling and cyclisation, again without any work up or isolation of intermediates, the overall yield of the process is increased.


According to a further aspect of the invention, therefore, we provide a process for the preparation of a compound of formula (I),



- 4 -


optionally in the form of its salt or complex, which comprises hydrolysing a compound of formula (IV) as defined above in the presence of acid, condensing the product of formula (V) formed

5




10 in situ in the presence of a base with a compound of formula (VI)

15



20 in which R represents CHO or H, followed by ring closure in situ of the resulting intermediate of formula (VII)

25



30

35 in which R represents CHO or H, to produce a compound of formula (I), which can then be optionally reacted with an acid or complexing agent to form its salt or complex.

- 5 -

As described above, preferred protecting groups in the compound of formula (IV) are acyl or substituted oxycarbonyl groups. Preferred acyl groups include formyl or lower alkanoyl (having e.g. 1 to 4 carbon atoms in the alkyl portion), especially an acetyl group. Preferred substituted oxycarbonyl groups will be of the formula R'OC(O)-, wherein R' may be an alkyl or aralkyl group. A preferred alkyl group is *tert* butyl; a preferred aralkyl group is benzyl.

The hydrolysis step is preferably achieved by mild acid-catalysed hydrolysis in an organic solvent, such as an alkanol, a cyclic ether or a chlorinated hydrocarbon. It is preferred to use an organic or mineral acid such as trifluoroacetic acid or hydrochloric acid in an alkanol solvent such as industrial methylated spirit (IMS), optionally in the presence of water.

The condensation step is then carried out without any isolation of the hydrolysis product of formula (V). This condensation reaction is preferably carried out under reflux in a polar solvent such as an alcohol, e.g. ethanol or butanol, or water or acetonitrile, or mixtures thereof, in the presence of at least sufficient base to neutralise both the acid used for the hydrolysis and that produced during the condensation. Generally, there will be at least 2 equivalents based on the amount of compound of formula (IV). The base will desirably be a trialkylamine or an alkali metal carbonate or bicarbonate, e.g. potassium or sodium carbonate, and more preferably, sodium bicarbonate. Preferred combinations are triethylamine or sodium bicarbonate in IMS. The group R in the compound of formula (VI) preferably represents CHO.


The ring closure reaction is then carried out, again without any isolation of any preceding intermediate

- 6 -

product of formula (VII). This is conveniently carried out using trialkylorthoformates in the presence of concentrated aqueous or anhydrous mineral acid, optionally in the presence of one or more non-aqueous solvents, e.g. tetrahydrofuran, ethyl acetate or IMS. Suitably, the unisolated product of formula (VII) is added to a mixture of acid and a trialkylorthoformate. A preferred combination comprises use of from about 1.5 to 3, preferably around 2 molar equivalents of hydrochloric acid in triethylorthoformate, which results in precipitation of the hydrochloride salt of the 9-substituted-2-amino purine of formula (I). The free base may, if desired, be liberated by treatment with base.


The process of the invention has been found to provide yields of compounds of formula (I) starting from a compound of formula (IV) of in excess of 80%. This compares very favourably with yields of compounds of formula (I) which are obtained using earlier stepwise procedures in which the intermediates are isolated, which give, typically around 56% when the compound of formula (III) is used as starting material, or yields of around 75% when the procedure described in Publication No. WO95/21161 is used, starting from a compound of formula (V).

The compounds of formula (VI) can be synthesised by a method as described in WO95/21161. The compound can be synthesised from the readily available 2,5-diamino-4,6-dihydroxypyrimidine, by reacting this with a Vilsmeier reagent of formula (VIII)



- 7 -

to form a compound of formula (IX)



10 (wherein in both formulae (VIII) and (IX), R_1 and R_2 are as defined in WO95/21161, viz: that R_1 and R_2 , which may be the same or different are selected from C_{1-8} straight-chain alkyl, C_{1-8} branched alkyl, C_{3-8} cycloalkyl, and aryl groups (such as phenyl or naphthyl), which may be optionally substituted, for example by C_{1-4} alkyl or

15 halogen (e.g. Cl). In a preferred embodiment of the invention R_1 and R_2 are both methyl), followed by hydrolysis.

20 Compounds of formula (VIII) may be prepared from a variety of formamides of secondary amines by reaction with a variety of acid halides, such as phosphorus oxychloride, phosphorus pentachloride, thionyl chloride, phosgene, and oxalyl chloride, for example as detailed in a review by C.M. Marson, Tetrahedron 1992, 48:3660-

25 3720 and references therein.

The compound of formula (VI) where R is H can be prepared from the compound of formula (IX) by hydrolysis in acidic solution, e.g. at $pH\ 3 \pm 0.5$, by adding a

30 water miscible cosolvent, such as ethanol. The compound of formula (VI) where R is CHO can also be prepared by the hydrolysis of the compound of formula (IX) in the minimum of water, with the pH controlled as described above. Under these conditions the compound of formula

35 (VI) where R is CHO precipitates as formed and can be filtered off.

- 8 -

The compound of formula (IV) may be prepared by methods analogous to those described in Tetrahedron: Asymmetry Vol.4, p.1117 (1993).

- 5 The following Examples are intended for illustration only and are not intended to limit the scope of the invention in any way.

- 9 -

Example A**Preparation of (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol hydrochloride salt.**

5 A suspension of (1R,4S)-cis-[4-(hydroxymethyl)-2-cyclopentene-1-yl] carbamic acid, 1, 1-dimethylethyl ester (100g) in industrial methylated spirit (IMS) (600ml) was treated with concentrated hydrochloric acid (48ml, 1.2 molar equivalents) and the resultant solution
10 was heated to the boil over about 0.5h. Heating under reflux was maintained for about 2.5h. The solution was cooled to 20 to 25°C and diluted with IMS (600ml). Triethylamine (170ml) was added followed by N-(2-amino-4,6-dichloro-5-pyrimidinyl)formamide (WO95/21161) (97g).
15 The suspension was heated under reflux for about 17h to give a clear solution, which was cooled to 25 to 30°C and finely divided potassium carbonate (169g) was added. The suspension was stirred in this temperature range for
20 about 0.5h then cooled to 0 to 5°C and the solids filtered off. The solids were washed with IMS (3 x 180ml and 1 x 140ml) and the combined filtrates and washings were concentrated under reduced pressure to a red gum. This was redissolved in IMS (1000ml) and the solution was
25 concentrated under reduced pressure to a gum. The dilution and re-concentration were repeated twice more, and the final gum was redissolved in IMS (350ml).

Meanwhile, a mixture of triethylorthoformate (900ml) and
30 tetrahydrofuran (THF) (400ml) was prepared and cooled to 0 to 5°C. Concentrated hydrochloric acid (80ml) was added, maintaining the temperature between 0 and 10°C, and more THF (100ml) was then added. To this mixture was added the IMS concentrate prepared above, which was
35 rinsed in with IMS (100ml). The mixture was warmed to 20 to 25°C and seeded with authentic (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol

- 10 -

hydrochloride salt and stirring continued for about 20h. The slurry was filtered, the solid was washed with a mixture of tert-butyl methyl ether and IMS (9/1, 3 x 300 ml) and dried in vacuo at 40 to 45°C to give the title compound (117g, 82%) as a fawn coloured solid ¹H-NMR (DMSO-d₆) δ: 8.38(s, 1, purine CH), 7.50(br m, ca 5, NH₃⁺, OH, HOD), 6.20(m, 1, =CH) 5.94(m, 1, =CH), 5.49(m, 1, NCH), 3.46(m, 2, OCH₂), 2.91(br m, 1, CH), 2.70-2.60(m, 1, CH), 1.75-1.66(m, 1, CH).

Example B

Preparation of (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol hydrochloride salt.

A suspension of (1R,4S)-cis-[4-(hydroxymethyl)-2-cyclopentene-1-yl] carbamic acid, 1, 1-dimethylethyl ester (100g) in industrial methylated spirit (IMS) (600ml) was treated with concentrated hydrochloric acid (48ml, 1.2 molar equivalents) and the resultant solution was heated to the boil over about 0.5h. Heating under reflux was maintained for about 3h. The solution was cooled to 20 to 25°C and sodium bicarbonate (103.4g) was added followed by N-(2-amino-4,6-dichloro-5-pyrimidinyl)formamide (WO95/21161) (97g) and IMS (600ml). The suspension was heated under reflux for about 4h and then cooled to about -5°C. After stirring at this temperature for about 1h, the solids were filtered off and washed with IMS (2 x 100ml). The combined filtrates and washings were concentrated under reduced pressure to a residual volume of about 400ml. This was redissolved in IMS (1000ml) and the solution was concentrated under reduced pressure to a gum. The dilution and re-concentration were repeated twice more, and the final gum was redissolved in IMS (350ml).

- 11 -

Meanwhile, triethylorthoformate (900ml) was cooled to 0 to 5°C and concentrated hydrochloric acid (80ml) was added, maintaining the temperature between 0 and 10°C. To this mixture was added the IMS concentrate prepared above, which was rinsed in with IMS (600ml). The mixture was warmed to 20 to 25°C and seeded with authentic (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol hydrochloride salt and stirring was continued for about 7h. The slurry was filtered, and the solid was washed with IMS (2 x 150ml) and dried in vacuo at 40 to 45°C to give the title compound (114g, 81%) as a fawn coloured solid, spectroscopically identical to the product of Example A.

15

Example C

20

Preparation of (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol hydrochloride salt.

25

30

35

A suspension of (1R,4S)-cis-[4-(hydroxymethyl)-2-cyclopentene-1-yl] carbamic acid, 1, 1-dimethylethyl ester (72.5kg) in industrial methylated spirit (IMS) (435L) and water (about 200L) was treated with concentrated hydrochloric acid (36.5L, 1.2 molar equivalents) and the resultant solution was heated to the boil over about 1.5h. Heating under reflux was maintained for about 2h. The solution was cooled to 20 to 25°C and sodium bicarbonate (75kg) was added followed by N-(2-amino-4,6-dichloro-5-pyrimidinyl)formamide (WO95/21161) (70kg) and IMS (435L). The suspension was heated under reflux for about 4h and then cooled to about -5°C. After stirring at this temperature for about 1h, the solids were filtered off and washed with IMS (2 x 144L). The combined filtrates and washings were concentrated under reduced pressure to a residual volume of about 290L. This was diluted with IMS (about

- 12 -

300L) and the solution was concentrated under reduced pressure to a residual volume of about 290L. The dilution and re-concentration were repeated twice more, and the final concentrate was diluted with IMS (610L) and heated to about 35-40°C. The resultant mixture was filtered and the solids were washed with IMS (2 x 144L). The combined filtrates and washings were concentrated under reduced pressure to a residual volume of about 290L and then diluted with IMS (217L).

Meanwhile, a mixture of triethylorthoformate (660L), concentrated hydrochloric acid (58L) and IMS (72L) was prepared at 0 to 8°C. To this mixture was added the IMS concentrate prepared above, which was rinsed in with IMS (2 x 72L). The mixture was warmed to 20 to 25°C and seeded with authentic (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol hydrochloride salt and stirring was continued for about 7h. The slurry was cooled to 18 - 21°C, filtered, and the solid was washed with IMS (72L and 217L) and dried in vacuo at 40 to 45°C to give the title compound (81.7kg, 79.5%) as a fawn coloured solid, spectroscopically identical to the product of Example A.

Example D

Preparation of (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol hydrochloride salt.

A suspension of (1R,4S)-cis-[4-(hydroxymethyl)-2-cyclopentene-1-yl] carbamic acid, 1, 1-dimethylethyl ester (10g) in industrial methylated spirit (IMS) (60ml) was treated with concentrated hydrochloric acid (5ml, 1.2 molar equivalents) and the resultant solution was heated to the boil over about 0.5h. Heating under reflux was maintained for about 3h. The solution was

- 13 -

cooled to 20 to 25°C and weighed (45.7g). A portion (14g) was diluted with IMS (14ml) and sodium bicarbonate (3.1g) was added followed by 2,5-diamino-4,6-dichloropyrimidine (W095/21161) (2.0g). The suspension was heated under reflux for about 7h and then cooled to about -5°C. The solids were filtered off and the combined filtrates and washings were concentrated under reduced pressure to a gum, which was redissolved in IMS (17ml).

10


Meanwhile, triethylorthoformate (21.4ml) was cooled to 0 to 5°C and concentrated hydrochloric acid (1.9ml) was added, maintaining the temperature between 0 and 10°C. To this mixture was added the IMS solution prepared above, which was rinsed in with IMS (2 x 2.5ml). The mixture was warmed to 20 to 25°C and seeded with authentic (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol hydrochloride salt and stirring was continued for about 19h. The slurry was filtered, and the solid was washed with IMS (2 x 4.5ml) and dried in vacuo at 40 to 45°C to give the title compound (2.06g, 61%) as a pale yellow solid, spectroscopically identical to the product of Example A.

20


- 14 -

Claims:


1. A process for the preparation of a compound of formula (I),




15 optionally in the form of its salt or complex,
which comprises hydrolysing a compound of formula (IV)



wherein P is a protecting group, in the presence of an acid, condensing the product of formula (V) formed




30 in situ in the presence of a base with a compound of formula (VI)



- 15 -

in which R represents CHO or H, followed by ring closure in situ of the resulting intermediate of formula (VII)



15 in which R represents CHO or H, to produce a compound of formula (I), which can then be optionally reacted with an acid or complexing agent to form its salt or complex.

2. A process as claimed in claim 1 wherein R is CHO.
- 20 3. A process as claimed in claim 1 or claim 2 wherein P is an acyl or substituted oxycarbonyl group.
4. A process as claimed in claim 3 wherein P is a formyl, C₁₋₄-alkanoyl group or oxycarbonyl group of formula R'OC(O) wherein R' is alkyl or aralkyl.
- 25 5. A process as claimed in claim 4 wherein P is an acetyl group or R' is tert butyl or benzyl.
- 30 6. A process as claimed in any of the preceding claims wherein the hydrolysis step is carried out in an alkanol, a cyclic ether or a chlorinated hydrocarbon in the presence of an organic or mineral acid.
- 35 7. A process as claimed in claim 6 wherein the hydrolysis step is carried out in IMS and the acid is trifluoroacetic acid or hydrochloric acid.

- 16 -

8. A process as claimed in any one of the preceding claims wherein the condensation reaction is carried out under reflux in a polar solvent in the presence of base.
- 5 9. A process as claimed in claim 8 wherein the polar solvent is an alcohol, water or acetonitrile and the base is a trialkylamine or an alkali metal carbonate or bicarbonate.
- 10 10. A process as claimed in claim 9 wherein the base is potassium or sodium carbonate or sodium bicarbonate.
11. A process as claimed in any of the preceding claims wherein the ring closure reaction is carried out using a
- 15 trialkylorthoformate in the presence of a mineral acid and optionally one or more non-aqueous solvents.
12. A process as claimed in claim 11 wherein the ring closure reaction is carried out using
- 20 triethylorthoformate in the presence of hydrochloric acid.
13. A process as claimed in claim 11 wherein the non-aqueous solvent is tetrahydrofuran, ethyl acetate or
- 25 IMS.
14. A process substantially as described in any of the preceding claims with reference to the Examples.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 98/03080

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D473/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	US 5 763 607 A (HUA MEI ET AL) 9 June 1998 Sheet 1 of 2. see example 11 ---	1-14
X	WO 95 21161 A (WELLCOME FOUND ; DALUGE SUSAN MARY (US); MARTIN MICHAEL TOLAR (US);) 10 August 1995 cited in the application see page 9, column 10; claim 9 ---	1-14
X	WO 91 15490 A (GLAXO INC ; VINCE ROBERT (US); PETERSON MARK LEE (US); LACKEY JOHN) 17 October 1991 cited in the application see page 4; claim 1 ---	1-14
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

12 January 1999

Date of mailing of the international search report

28/01/1999

Name and mailing address of the ISA
European Patent Office, P. B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx: 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gettins, M

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/GB 98/03080

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 434 450 A (WELLCOME FOUND) 26 June 1991 cited in the application see page 8; example 4 -----	1-14
X	GB 2 217 320 A (UNIV MINNESOTA) 25 October 1989 cited in the application see page 18; example 9 -----	1-14
A	US 5 329 008 A (PARTRIDGE JOHN J ET AL) 12 July 1994 see example 2 -----	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

In ternational Application No

PCT/GB 98/03080

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5763607 A	09-06-1998	US 5631370 A	20-05-1997
		US 4931559 A	05-06-1990
		US 4916224 A	10-04-1990
		US 5567703 A	22-10-1997
		US 5175292 A	29-12-1992
		AT 397801 B	25-07-1994
		AT 10689 A	15-11-1993
		AU 637015 B	13-05-1993
		AU 626278 B	30-07-1992
		AU 2867189 A	20-07-1989
		BE 1003815 A	23-06-1992
		CA 1339803 A	07-04-1998
		CH 679152 A	31-12-1991
		DE 3901502 A	27-07-1989
		DK 23489 A	21-07-1989
		EP 0325460 A	26-07-1989
		ES 2052897 T	16-07-1994
		FI 890286 A, B,	21-07-1989
		FR 2626002 A	21-07-1989
		GB 2217320 A, B	25-10-1989
		GB 2243609 A, B	06-11-1991
		GR 89100033 A	31-03-1994
		GR 3006490 T	21-06-1993
		IE 62275 B	25-01-1995
		IL 88999 A	29-12-1994
		JP 2196788 A	03-08-1990
		JP 2793825 B	03-09-1998
		JP 1308282 A	12-12-1989
		JP 2738946 B	08-04-1998
		KR 127137 B	29-12-1997
		LU 87437 A	30-08-1989
		NL 8900122 A	16-08-1989
		OA 9031 A	31-03-1991
		PL 163814 B	31-05-1994
		PT 89482 A, B	04-10-1989
		SE 505213 C	14-07-1997
		SE 8900192 A	19-01-1989
		SI 8910123 A	30-04-1997
		CN 1036015 A, B	04-10-1989
		MX 14597 A	01-08-1993
		RU 2067097 C	27-09-1990
		US 4950758 A	21-08-1990
WO 9521161 A	10-08-1995	AU 690203 B	23-04-1998
		AU 1543895 A	21-08-1995
		BR 9506667 A	16-09-1997
		CA 2182105 A	10-08-1995
		CN 1139924 A	08-01-1997
		EP 0741710 A	13-11-1996
		FI 963070 A	02-08-1996
		HU 75300 A	28-05-1997
		JP 9508412 T	26-08-1997
		NO 963239 A	02-10-1996
		NZ 278948 A	26-01-1998
		PL 315713 A	25-11-1996
		SG 47918 A	17-04-1998
WO 9115490 A	17-10-1991	US 5126452 A	30-06-1992

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/03080

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9115490 A		EP 0487658 A	03-06-1992
		US 5241069 A	31-08-1993
EP 0434450 A	26-06-1991	AP 196 A	30-06-1992
		AU 633672 B	04-02-1993
		AU 6841990 A	27-06-1991
		CA 2033044 A	23-06-1991
		CN 1054981 A,B	02-10-1991
		CZ 9202470 A	15-04-1998
		CZ 9006583 A	12-11-1997
		FI 906367 A	23-06-1991
		FI 970666 A	17-02-1997
		IL 96748 A	31-07-1995
		MX 9203215 A	01-07-1992
		NZ 236593 A	26-01-1994
		PL 167097 B	31-07-1995
		PT 96321 A,B	30-09-1991
		SG 49685 A	15-06-1998
		RU 2068849 C	10-11-1996
		RU 2091386 C	27-09-1997
		US 5206435 A	27-04-1993
GB 2217320 A	25-10-1989	US 4916224 A	10-04-1990
		US 4931559 A	05-06-1990
		AT 397801 B	25-07-1994
		AT 10689 A	15-11-1993
		AU 637015 B	13-05-1993
		AU 626278 B	30-07-1992
		AU 2867189 A	20-07-1989
		BE 1003815 A	23-06-1992
		CA 1339803 A	07-04-1998
		CH 679152 A	31-12-1991
		CN 1036015 A,B	04-10-1989
		DE 3901502 A	27-07-1989
		DK 23489 A	21-07-1989
		EP 0325460 A	26-07-1989
		ES 2052897 T	16-07-1994
		FI 890286 A,B,	21-07-1989
		FR 2626002 A	21-07-1989
		GB 2243609 A,B	06-11-1991
		GR 89100033 A	31-03-1994
		GR 3006490 T	21-06-1993
		IE 62275 B	25-01-1995
		IL 88999 A	29-12-1994
		JP 2196788 A	03-08-1990
		JP 2793825 B	03-09-1998
		JP 1308282 A	12-12-1989
		JP 2738946 B	08-04-1998
		KR 127137 B	29-12-1997
		LU 87437 A	30-08-1989
		MX 14597 A	01-08-1993
		NL 8900122 A	16-08-1989
		OA 9031 A	31-03-1991
		PL 163814 B	31-05-1994
		PT 89482 A,B	04-10-1989
		SE 505213 C	14-07-1997
		SE 8900192 A	19-01-1989
		SI 8910123 A	30-04-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/03080

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2217320 A		RU 2067097 C	27-09-1990
		US 4950758 A	21-08-1990
		US 5631370 A	20-05-1997
		US 5567703 A	22-10-1996
		US 5175292 A	29-12-1992
		US 5763607 A	09-06-1998
<hr/>			
US 5329008 A	12-07-1994	US 5576430 A	19-11-1996
<hr/>			